CGS 15435 is a potent thromboxen (TxA2) synthetase inhibitor (IC50: 1 nM). CGS 15435 acts on PGI2 synthase, cyclooxygenase and liposynthase with much less selectivity than on thromboxin synthase.

TXA2:1 nM

CGS 15435 inhibited the formation of PGE2 (IC50:1200 μM), PGI2 synthetase (IC50:90 μM) and 5-lipoxygenase (IC50:60 μM).[1]

The effect of CGS 15435 was long lasting, as the increase of plasma TxB2 levels was prevented even 24 hours after the administration of CGS 15435. CGS 15435 inhibited the formation of TxB2 significantly at 4, 6, 12 and 24 h after administration. Administration of CGS 15435 0.25 or 24 h before arachidonic acid (AA) did not increase TxB2 in surviving animals (4/4 and 5/6, respectively). The final TxB2 level in CGS15435A(pretreatment for 0.25 and 24 h) groups was significantly lower than that in arachidonic acid (AA) and daxibon (pretreatment for 2 h) groups.[1]